cagrilintide news New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Cagrilintide - Mile High Compounds

Slow dose escalation is the primary tool for managing GI discomfort

TB-500 corresponds to the active region of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in regulating the actin cytoskeleton

BPC-157 is a regenerative peptide that supports tissue repair, gut healing and inflammation control

With this said, we look at functional ranges which are much tighter because we are looking for functional imbalances as opposed to a clinical disease

a peptide spanning 15 amino acids in length) derived from a partial fragment of human gastric juice protein known as Body Protection Compound (BPC)

What are the Potential Risks